CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation

Alessandra Stasia, Anna Ghiso, Federica Galaverna, Anna Maria Raiola, Francesca Gualandi, Silvia Luchetti, Sarah Pozzi, Riccardo Varaldo, Teresa Lamparelli, Stefania Bregante, Maria Teresa Van Lint, Carmen di Grazia, Andrea Bacigalupo

Research output: Contribution to journalArticlepeer-review


Poor graft function (PGF) is characterized by pancytopenia and a hypoplastic marrow, with complete donor chimerism, usually without severe graft-versus-host disease (GVHD). We report 41 patients with PGF, treated with granulocyte colony-stimulating factor-mobilized CD34 selected cells, at a median interval from transplant of 140days, without conditioning and without GVHD prophylaxis. Donors were HLA matched siblings (n=12), unrelated donors (n=18), or mismatched family members (n=11). The median number of infused CD34+ cells was 3.4×106/kg. The rate of trilineage recovery was 75%: 83% for HLA matched siblings and 72% for unrelated and mismatched family members (P=3). The cumulative incidence of acute grade II GVHD was 15%, and no patient developed de novo chronic GVHD. The actuarial 3-year survival is 63%: 76% and 25% for patients with or without trilineage recovery. These data confirm the role of CD34+ selected cells from the same donor in the treatment of PGF and warrant the request for a second donation also when the donor is unrelated.

Original languageEnglish
Pages (from-to)1440-1443
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Issue number9
Publication statusPublished - 2014


  • Allogeneic stem cell transplants
  • CD34
  • GVHD
  • Poor graft function
  • Rejection

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)


Dive into the research topics of 'CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this